Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616680487> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2616680487 abstract "Objective: To compare cardiovascular (CV) outcomes between patients initiating adjunct therapy with either niacin extended-release (NER) for broader lipid panel management or ezetimibe (EZE) for continued LDL-C reduction. Methods: Statin-treated patients aged ≥30 augmenting with NER or EZE between 1/1/05-11/30/09 (Index Date) were identified. Patients with ≥12 months of health plan eligibility before the Index Date (baseline) were included, and patients with secondary risk and ≥1 full lipid panel were retained. A propensity score (PPS) model was developed controlling for the following baseline factors: age, gender, geographic region, type of health coverage, baseline lipids, mode of therapy augmentation, potency of adjunct statin therapy, baseline statin adherence, comorbidities, and alternative CV medications. NER and EZE patients were matched based on PPS. Clinical outcomes included incidence of a major adverse cardiovascular event (MACE). MACE was defined as a composite of acute ischemic heart (IHD), peripheral vascular (PVD), and cerebrovascular disease (CVD) events. The economic outcome was annual CV disease-related costs. These outcomes were compared using univariate Cox proportional hazards and generalized linear models respectively. Results: A total of 15,195 patients initiated adjunct therapy with NER (n=3,098) and EZE (n=12,097) meeting all study criteria. Post-PPS match, 2,261 patients were identified in each cohort with no statistically significant differences in baseline or concurrent treatment characteristics. Frequency of MACE was lower among NER patients (3.5%) vs. EZE (5.4%), with a hazard ratio (HR) of 0.89 (95% CI: 0.67-1.20). Specifically, NER patients demonstrated a lower risk of IHD (HR: 0.90; 95% CI: 0.65-1.25) and CVD (HR: 0.69; 95% CI: 0.34-1.41) events vs. EZE patients. These findings correspond to significantly lower adjusted annual cost among NER patients ($8,168; 95% CI: $7,720 - $8,641) vs. EZE ($9,030; 95% CI: $8,535 - $9,553) ( P= 0.0136). Conclusions: Positive clinical benefits observed in this broader naturalistic population are consistent with results from recent clinical trials and suggest that treating beyond LDL-C with statin + NER in secondary risk patients may reduce CV risk and associated costs." @default.
- W2616680487 created "2017-05-26" @default.
- W2616680487 creator A5027085455 @default.
- W2616680487 creator A5039832713 @default.
- W2616680487 creator A5086835788 @default.
- W2616680487 date "2011-11-01" @default.
- W2616680487 modified "2023-09-26" @default.
- W2616680487 title "Abstract P246: A Naturalistic Assessment of Lipid Treatment Strategies: Further LDL-C Reduction Versus Comprehensive Lipid Management" @default.
- W2616680487 doi "https://doi.org/10.1161/circoutcomes.4.suppl_2.ap246" @default.
- W2616680487 hasPublicationYear "2011" @default.
- W2616680487 type Work @default.
- W2616680487 sameAs 2616680487 @default.
- W2616680487 citedByCount "0" @default.
- W2616680487 crossrefType "journal-article" @default.
- W2616680487 hasAuthorship W2616680487A5027085455 @default.
- W2616680487 hasAuthorship W2616680487A5039832713 @default.
- W2616680487 hasAuthorship W2616680487A5086835788 @default.
- W2616680487 hasConcept C126322002 @default.
- W2616680487 hasConcept C197934379 @default.
- W2616680487 hasConcept C207103383 @default.
- W2616680487 hasConcept C2776839432 @default.
- W2616680487 hasConcept C2776933373 @default.
- W2616680487 hasConcept C2777482532 @default.
- W2616680487 hasConcept C2778375690 @default.
- W2616680487 hasConcept C2778657065 @default.
- W2616680487 hasConcept C2780400711 @default.
- W2616680487 hasConcept C2780739214 @default.
- W2616680487 hasConcept C44249647 @default.
- W2616680487 hasConcept C500558357 @default.
- W2616680487 hasConcept C50382708 @default.
- W2616680487 hasConcept C71924100 @default.
- W2616680487 hasConcept C72563966 @default.
- W2616680487 hasConceptScore W2616680487C126322002 @default.
- W2616680487 hasConceptScore W2616680487C197934379 @default.
- W2616680487 hasConceptScore W2616680487C207103383 @default.
- W2616680487 hasConceptScore W2616680487C2776839432 @default.
- W2616680487 hasConceptScore W2616680487C2776933373 @default.
- W2616680487 hasConceptScore W2616680487C2777482532 @default.
- W2616680487 hasConceptScore W2616680487C2778375690 @default.
- W2616680487 hasConceptScore W2616680487C2778657065 @default.
- W2616680487 hasConceptScore W2616680487C2780400711 @default.
- W2616680487 hasConceptScore W2616680487C2780739214 @default.
- W2616680487 hasConceptScore W2616680487C44249647 @default.
- W2616680487 hasConceptScore W2616680487C500558357 @default.
- W2616680487 hasConceptScore W2616680487C50382708 @default.
- W2616680487 hasConceptScore W2616680487C71924100 @default.
- W2616680487 hasConceptScore W2616680487C72563966 @default.
- W2616680487 hasIssue "suppl_2" @default.
- W2616680487 hasLocation W26166804871 @default.
- W2616680487 hasOpenAccess W2616680487 @default.
- W2616680487 hasPrimaryLocation W26166804871 @default.
- W2616680487 hasRelatedWork W1527954202 @default.
- W2616680487 hasRelatedWork W2260814497 @default.
- W2616680487 hasRelatedWork W2293597243 @default.
- W2616680487 hasRelatedWork W2313313525 @default.
- W2616680487 hasRelatedWork W2331310316 @default.
- W2616680487 hasRelatedWork W2473272179 @default.
- W2616680487 hasRelatedWork W2510965028 @default.
- W2616680487 hasRelatedWork W2551175966 @default.
- W2616680487 hasRelatedWork W2559540579 @default.
- W2616680487 hasRelatedWork W2680986483 @default.
- W2616680487 hasRelatedWork W2711471276 @default.
- W2616680487 hasRelatedWork W2748868481 @default.
- W2616680487 hasRelatedWork W2755934114 @default.
- W2616680487 hasRelatedWork W2887032743 @default.
- W2616680487 hasRelatedWork W2894645224 @default.
- W2616680487 hasRelatedWork W2910633658 @default.
- W2616680487 hasRelatedWork W2939642169 @default.
- W2616680487 hasRelatedWork W2989190856 @default.
- W2616680487 hasRelatedWork W2996398337 @default.
- W2616680487 hasRelatedWork W3101626174 @default.
- W2616680487 hasVolume "4" @default.
- W2616680487 isParatext "false" @default.
- W2616680487 isRetracted "false" @default.
- W2616680487 magId "2616680487" @default.
- W2616680487 workType "article" @default.